Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Change in Acquisitions & Divestments (2017 - 2025)

Corcept Therapeutics' Change in Acquisitions & Divestments history spans 9 years, with the latest figure at $132.0 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments rose 64.37% year-over-year to $132.0 million; the TTM value through Dec 2025 reached $389.6 million, down 5.64%, while the annual FY2025 figure was $389.6 million, 5.64% down from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $132.0 million at Corcept Therapeutics, up from $52.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $207.5 million in Q1 2023 and bottomed at -$258.4 million in Q4 2021.
  • The 5-year median for Change in Acquisitions & Divestments is $79.9 million (2022), against an average of $75.7 million.
  • The largest annual shift saw Change in Acquisitions & Divestments skyrocketed 392.5% in 2023 before it tumbled 71.23% in 2025.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at -$258.4 million in 2021, then soared by 130.74% to $79.4 million in 2022, then crashed by 40.83% to $47.0 million in 2023, then surged by 70.92% to $80.3 million in 2024, then skyrocketed by 64.37% to $132.0 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Change in Acquisitions & Divestments are $132.0 million (Q4 2025), $52.0 million (Q3 2025), and $93.5 million (Q2 2025).